Solventum Corporation (SOLV) Stock Price, Quote & News

Company Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature m...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 651 733 1110

Website: www.solventum.com

Address:

3M Center, Building 275-6W-20 2510 Conway Avenue East St. Paul, Maplewood, United States

Stoop_Kid Aug. 19 at 7:45 PM

$SOLV wake this dawg up @Doozio

1 · Reply

VDIVICI Aug. 16 at 11:43 PM

$SOLV I sold my off last night I only got a few because of the 3m collab

0 · Reply

topstockalerts Aug. 15 at 12:48 PM

Trade Desk is the S&P 500’s worst YTD performer, down 38% since joining the index on July 18 and 33% since being named to it on July 14. While S&P inclusion is often viewed as a milestone, Dow Jones data shows less than half of 2024’s ~two dozen new entrants were up a month after joining; average 1-month return was -2.8% vs. the SPX’s +1.8%. TTD faces a growth slowdown expected to persist this quarter, with Jefferies citing rising ad-market competition despite management downplaying threats from AMZN. New entrant returns this year ranged from SOLV -26% to PLTR +117%. $AMZN $PLTR $SOLV $TTD

1 · Reply

DonCorleone77 Aug. 14 at 10:57 AM

$SOLV Solventum 8.8M share Spot Secondary priced at $73.65

0 · Reply

StockAutoPro Aug. 14 at 1:24 AM

$SOLV: Buy target $72.38 Sell target $78.1 Strong financials and rising demand make this SOLV sector stock a promising long-term investment.

0 · Reply

StockAutoPro Aug. 12 at 4:15 AM

$SOLV: Buy target $69.86 Sell target $75.45 Solar energy company demonstrating consistent growth, a good potential long-term investment in the renewable sector.

0 · Reply

ZacksResearch Aug. 8 at 4:55 PM

$SOLV beats estimates with a strong Q2, but why the Sell rating? 🤔 📈 EPS of $1.69 beats consensus by 16.6% 📊 Reported revenue up 3.9% YoY, driven by growth across all segments including MedSurg and HIS 🔍 Despite solid results, SOLV carries a Zacks Rank #4 (Sell) Is the restructuring program causing uncertainty? Full analysis here 👉 https://www.zacks.com/stock/news/2683958/solventum-stock-gains-on-q2-earnings-revenue-beat-margins-improve?cid=sm-stocktwits-2-2683958-body-6819&ADID=SYND_STOCKTWITS_TWEET_2_2683958_BODY_6819

0 · Reply

ZacksResearch Aug. 8 at 1:11 PM

$SOLV pops 5% on Q2 beat — is this just the beginning? Earnings and revenue topped estimates, margins improved, and EPS outlook is now higher thanks to broad-based segment growth. Full breakdown here 👉 https://www.zacks.com/stock/news/2683958/solventum-stock-gains-on-q2-earnings-revenue-beat-margins-improve?cid=sm-stocktwits-2-2683958-teaser-6816&ADID=SYND_STOCKTWITS_TWEET_2_2683958_TEASER_6816

0 · Reply

swaggerleebob Aug. 8 at 11:37 AM

$SOLV

0 · Reply

JarvisFlow Aug. 8 at 11:31 AM

Piper Sandler has adjusted their stance on Solventum ( $SOLV ), setting the rating to Overweight with a target price of 87 → 94.

0 · Reply

Solventum Announces $1.75 Billion Note Tender Offers

Aug 13, 2025, 10:39 PM EDT - 13 days ago

Solventum Announces Pricing of Secondary Offering of Common Stock

Aug 13, 2025, 4:48 PM EDT - 14 days ago

Solventum Announces Launch of Secondary Offering of Common Stock

Aug 8, 2025, 6:53 AM EDT - 19 days ago

Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:52 PM EDT - 20 days ago

Solventum raises annual profit forecast on strength in surgical equipment

Aug 7, 2025, 4:05 PM EDT - 20 days ago

Solventum Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 9:12 AM EDT - 5 weeks ago

Solventum: Appealing Again

Jul 17, 2025, 4:05 PM EDT - 5 weeks ago

Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

Jun 18, 2025, 10:00 AM EDT - 2 months ago

Solventum Named a Best Company to Work for by U.S. News & World Report

Jun 3, 2025, 4:05 PM EDT - 3 months ago

Solventum to Participate in the 2025 Goldman Sachs Health Care Conference

May 11, 2025, 5:07 PM EDT - 3 months ago

Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript

May 9, 2025, 11:02 AM EDT - 3 months ago

Solventum Corporation: Cheap, With Caveats

May 8, 2025, 6:11 PM EDT - 3 months ago

Solventum beats first-quarter profit estimates on strong surgical product sales

May 8, 2025, 4:05 PM EDT - 3 months ago

Solventum to Participate in the 2025 BofA Securities Health Care Conference

May 8, 2025, 4:05 PM EDT - 3 months ago

Solventum Reports First Quarter 2025 Financial Results

Apr 17, 2025, 4:05 PM EDT - 4 months ago

Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

Mar 25, 2025, 6:00 PM EDT - 5 months ago

Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

Mar 21, 2025, 12:44 PM EDT - 5 months ago

3M Spin Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy

Mar 20, 2025, 9:00 AM EDT - 5 months ago

Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day

Mar 12, 2025, 8:12 AM EDT - 6 months ago

Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance

Feb 28, 2025, 8:36 AM EST - 6 months ago

Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 5:09 PM EST - 6 months ago

Solventum forecasts annual profit above estimates on strong surgical product sales

Feb 27, 2025, 4:05 PM EST - 6 months ago

Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance

Feb 26, 2025, 4:15 PM EST - 6 months ago

Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City

Feb 26, 2025, 3:37 PM EST - 6 months ago

Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports

Feb 26, 2025, 2:50 PM EST - 6 months ago

Trian Comments on Solventum's Sale of its Purification & Filtration Business

TMO

Feb 25, 2025, 10:16 AM EST - 6 months ago

Solventum In The Early Stages Of A Multiyear Turnaround Effort

Feb 25, 2025, 8:56 AM EST - 6 months ago

Thermo Fisher buys Solventum's purification and filtration business for $4.1 billion

TMO

Feb 25, 2025, 8:39 AM EST - 6 months ago

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

TMO

Feb 25, 2025, 8:32 AM EST - 6 months ago

Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business

TMO

Feb 11, 2025, 8:00 AM EST - 7 months ago

Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

Feb 5, 2025, 10:00 AM EST - 7 months ago

Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging

Jan 30, 2025, 4:05 PM EST - 7 months ago

Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025

Jan 8, 2025, 1:38 PM EST - 8 months ago

Peltz's Trian Fund says 3M's Solventum spin-off not living up to potential

Jan 8, 2025, 1:01 PM EST - 8 months ago

Trian Issues Open Letter to Solventum Shareholders

Jan 8, 2025, 6:30 AM EST - 8 months ago

The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

Nov 19, 2024, 6:50 AM EST - 10 months ago

Solventum to Participate in the Piper Sandler Healthcare Conference

Nov 14, 2024, 9:00 AM EST - 10 months ago

Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment

Nov 8, 2024, 5:16 PM EST - 10 months ago

Solventum Corporation (SOLV) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:47 PM EST - 10 months ago

Solventum raises annual profit forecast on strong surgical product sales

Nov 7, 2024, 4:05 PM EST - 10 months ago

Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance

Oct 24, 2024, 11:33 AM EDT - 10 months ago

Solventum Taps Bankers to Explore Sale of Filtration Unit

Oct 15, 2024, 6:50 AM EDT - 11 months ago

Solventum to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024

Oct 14, 2024, 7:00 AM EDT - 11 months ago

Solventum Announces Commitment to 100% Renewable Electricity by 2030

Oct 10, 2024, 9:00 AM EDT - 11 months ago

Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

Oct 9, 2024, 12:17 PM EDT - 11 months ago

Buy 4 October Dividend Aristocrats & Watch 10

ADM AMCR BEN CVX ED FAST FRT

Sep 10, 2024, 1:25 PM EDT - 1 year ago

Buy 4 September Dividend Aristocrats And Watch 6

AMCR APD BEN CVX FAST FRT GPC

Sep 10, 2024, 6:45 AM EDT - 1 year ago

Solventum Launches All-In-One, Extended-Wear Wound Dressing for V.A.C.® Therapy

Aug 28, 2024, 6:50 AM EDT - 1 year ago

Solventum to Participate in Upcoming Investor Conferences

Aug 26, 2024, 11:55 AM EDT - 1 year ago

Lanny's Stock Sales Through June 30, 2024

CIM MDU MMM PSKY

Stoop_Kid Aug. 19 at 7:45 PM

$SOLV wake this dawg up @Doozio

1 · Reply

VDIVICI Aug. 16 at 11:43 PM

$SOLV I sold my off last night I only got a few because of the 3m collab

0 · Reply

topstockalerts Aug. 15 at 12:48 PM

1 · Reply

DonCorleone77 Aug. 14 at 10:57 AM

$SOLV Solventum 8.8M share Spot Secondary priced at $73.65

0 · Reply

StockAutoPro Aug. 14 at 1:24 AM

$SOLV: Buy target $72.38 Sell target $78.1 Strong financials and rising demand make this SOLV sector stock a promising long-term investment.

0 · Reply

StockAutoPro Aug. 12 at 4:15 AM

$SOLV: Buy target $69.86 Sell target $75.45 Solar energy company demonstrating consistent growth, a good potential long-term investment in the renewable sector.

0 · Reply

ZacksResearch Aug. 8 at 4:55 PM

0 · Reply

ZacksResearch Aug. 8 at 1:11 PM

0 · Reply

swaggerleebob Aug. 8 at 11:37 AM

$SOLV

0 · Reply

JarvisFlow Aug. 8 at 11:31 AM

Piper Sandler has adjusted their stance on Solventum ( $SOLV ), setting the rating to Overweight with a target price of 87 → 94.

0 · Reply

Optiongenius Aug. 8 at 2:11 AM

$SOLV OPEN?

0 · Reply

HottyToddy172 Aug. 7 at 9:30 PM

$SOLV Nice AH pop!

0 · Reply

OptionRunners Aug. 7 at 8:32 PM

$SOLV +4% so far

1 · Reply

OptionRunners Aug. 7 at 3:54 PM

$SOLV Buyer of the September 19th $75 calls 2,200 times for $2.60 ahead of earnings tonight

1 · Reply

Doozio Aug. 7 at 3:41 PM

Well they gapped da HALO on eps n it was always 🐒🍌🧠⏰♾️ to $SOLV this 🐑 💩 on a FRYday eps gap n go.

0 · Reply

ZacksResearch Aug. 5 at 5:05 PM

$SOLV Q2 earnings preview: Will the recent three-phase transformation plan pay off? 🤔 Solventum's MedSurg segment shows solid demand, but Q2 faces growth moderation due to ERP impacts. With a trailing four-quarter average earnings surprise of 11.48% and a Zacks Rank #4, the earnings beat isn't looking likely this time. 📉 Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2668277/can-solventum-sustain-growth-amid-tariff-headwinds-in-q2-earnings?cid=sm-stocktwits-2-2668277-body-6128&ADID=SYND_STOCKTWITS_TWEET_2_2668277_BODY_6128

0 · Reply

ZacksResearch Aug. 5 at 3:37 PM

$SOLV faces a real Q2 stress test — can growth outrun tariffs? Strong segment performance is expected, but ERP implementation and tariff headwinds could pressure margins. Full earnings setup here 👉 https://www.zacks.com/stock/news/2668277/can-solventum-sustain-growth-amid-tariff-headwinds-in-q2-earnings?cid=sm-stocktwits-2-2668277-teaser-6044&ADID=SYND_STOCKTWITS_TWEET_2_2668277_TEASER_6044

0 · Reply

teksviler Jul. 18 at 8:29 PM

$SOLV $PWR $VST $RBRK Life is good 😊

0 · Reply

stockpicker63 Jul. 15 at 1:57 PM

Watch today! $CRC, $APG , $SOLV and $ETN

0 · Reply

JarvisFlow Jul. 15 at 1:01 PM

Morgan Stanley has updated their rating for Solventum ( $SOLV ) to Overweight with a price target of 103.

0 · Reply

michaeljohn1919 Jul. 14 at 10:35 PM

$SOLV quiet before the storm?!⛈️

0 · Reply

JarvisFlow Jul. 1 at 2:22 PM

Argus Research has updated their rating for Solventum ( $SOLV ) to Buy.

0 · Reply

Market Cap	12.61B
Revenue (ttm)	8.25B
Net Income (ttm)	478.00M
EPS (ttm)	N/A
PE Ratio	13.16
Forward PE	12.48
Profit Margin	5.79%
Debt to Equity Ratio	2.14

Volume	868,414
Avg Vol	942,930
Day's Range	N/A - N/A
Shares Out	173.39M
Stochastic %K	56%
Beta	0.52
Analysts	Sell
Price Target	$87.12